Last reviewed · How we verify
APG-115
APG-115 is a small molecule inhibitor of BCL-2 family proteins.
APG-115 is a small molecule inhibitor of BCL-2 family proteins. Used for Relapsed or refractory multiple myeloma.
At a glance
| Generic name | APG-115 |
|---|---|
| Also known as | alrizomadlin |
| Sponsor | Ascentage Pharma Group Inc. |
| Drug class | BCL-2 inhibitor |
| Target | BCL-2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
APG-115 works by selectively inhibiting the BCL-2 family proteins, which are involved in regulating cell death and survival. This inhibition can lead to the induction of apoptosis in cancer cells. By targeting these proteins, APG-115 aims to selectively kill cancer cells while sparing normal cells.
Approved indications
- Relapsed or refractory multiple myeloma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma (PHASE2)
- APG-115 in Salivary Gland Cancer Trial (PHASE1, PHASE2)
- A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL (PHASE2)
- A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors (PHASE1, PHASE2)
- Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST (PHASE1, PHASE2)
- APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors (PHASE1, PHASE2)
- APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors (PHASE1)
- A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- APG-115 CI brief — competitive landscape report
- APG-115 updates RSS · CI watch RSS
- Ascentage Pharma Group Inc. portfolio CI